Drug Profile
Research programme: anti-fungals - Astellas
Alternative Names: AS 2077715Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses in Japan (PO)
- 15 Sep 2009 Preclinical trials in Mycoses in Japan (unspecified route)